-
Issue Information Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-07
Click on the article title to read more.
-
A Transfusion Reaction due to Anti‐ER5 in a Hyposplenic β0 Thalassemia Major Patient Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-07 Arun Thomas, Kirstin Lund, Viviene Ballon, Barbara J. Bain
A 6-year-old boy of Libyan ethnic origin was referred to pediatric hematology 3 months after entering the United Kingdom as a refugee. The child was known to have thalassemia major. His parents were first cousins. He had previously been transfused every 4 weeks, received chelation therapy and had been splenectomized. More recently, transfusion requirement had increased to every 2 weeks and he had developed
-
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-07 Samuel Yamshon, Jean L. Koff, Melissa C. Larson, Brad S. Kahl, Carla Casulo, Izidore S. Lossos, Sara Haddadi, Michele Stanchina, Dai Chihara, Amy Ayers, Thomas M. Habermann, Yucai Wang, Arushi Khurana, Grzegorz S. Nowakowski, Tanner W. Reicks, Umar Farooq, Brian K. Link, Jonathon B. Cohen, Peter Martin, Jia Li, Ashwini Shewade, Connie Lee Batlevi, Andrea Lo‐Rossi, David Fox, Anthony Masaquel, Yong
-
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development Blood Cancer J. (IF 12.9) Pub Date : 2025-02-07 Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial
-
Multicenter Prospective First-Line Helicobacter Pylori Eradication for Localized Gastric “Pure” Diffuse Large B-Cell Lymphoma Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-06 Li-Tzong Chen, Kun-Huei Yeh, Chung-Wu Lin, Tsang-En Wang, Ming-Chung Wang, Chin-Fu Hsiao, Chieh-Chang Chen, Jyh-Ming Liou, Hsiu-Po Wang, Ming-Feng Wei, Hsiao-Wei Lee, Chia-Tung Shun, Tsang-Wu Liu, Hwei-Fang Tien, Ming-Shiang Wu, Sung-Hsin Kuo, Ann-Lii Cheng
-
Correspondence to: “Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations”, Curik N et al. Leukemia. 2024; 38: 1415–1418 Leukemia (IF 12.8) Pub Date : 2025-02-06 Seiichi Okabe, Yuya Arai, Akihiko Gotoh
-
VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target Leukemia (IF 12.8) Pub Date : 2025-02-06 Ophélie Champion, Sophie Maïga, Chloé Antier, Christelle Dousset, Agnès Moreau-Aubry, Céline Bellanger, François Guillonneau, Géraldine Descamps, Jose Antonio Moreno, Ohyun Kwon, Nicoletta Libera Lilli, Philippe Moreau, David Chiron, Catherine Pellat-Deceunynck, Cyrille Touzeau, Patricia Gomez-Bougie
-
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry Blood Cancer J. (IF 12.9) Pub Date : 2025-02-06 Cecilia Bonolo de Campos, Chantal E. McCabe, Laura A. Bruins, Daniel R. O’Brien, Sochilt Brown, Renee C. Tschumper, Cristine Allmer, Yuan Xiao Zhu, Kari G. Rabe, Sameer A. Parikh, Neil E. Kay, Huihuang Yan, James R. Cerhan, John N. Allan, Richard R. Furman, J. Brice Weinberg, Danielle M. Brander, Diane F. Jelinek, Marta Chesi, Susan L. Slager, Esteban Braggio
-
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy Blood Cancer J. (IF 12.9) Pub Date : 2025-02-05 Luciano J. Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai R. Dholaria, Kelly N. Godby, Susan Bal, Gayathri Ravi, Smith Giri, Saurabh Chhabra, Rebecca Silbermann, Natalie S. Callander
-
Targeting Caseinolytic Mitochondrial Matrix Peptidase, a Novel Contributor to High-risk Behavior, in Multiple Myeloma. Blood (IF 21.0) Pub Date : 2025-02-06 Li Qin,Luz Yurany Moreno Rueda,Upasana Ray,Iqbal Mahmud,Lin Tan,Philip L Lorenzi,Suyu Liu,Heather Yan Lin,David E Mery,Fenghuang Zhan,John D Shaughnessy,Qing Yi,Maria Jose Acevedo Calado,Hua Wang,Elisabet E Manasanch,Hans C Lee,Krina K Patel,Isere Kuiatse,David E Symer,Robert Z Orlowski
Plasma cell dyscrasias encompass a spectrum from the precursors monoclonal gammopathy of undetermined significance and smoldering myeloma to symptomatic myeloma, but the genes that enable progression and confer poor prognosis are incompletely understood. Using single cell transcriptomics, we identified the Caseinolytic protease proteolytic subunit (CLPP), a key component of the mitochondrial CLP serine
-
Impact of new medications on the treatment of Immune TTP. Blood (IF 21.0) Pub Date : 2025-02-06 Marie Scully,Lara Howells,William A Lester
The last decade has seen the introduction of two new licensed therapies for thrombotic thrombocytopenic purpura (TTP)-caplacizumab and recombinant ADAMTS 13 (rADAMTS 13), for immune (iTTP) and congenital TTP (cTTP) respectively. They improve acute TTP outcomes, reduce the need for plasma therapy, time to clinical response and treatment burden. Future pathways need to replace plasma exchange in acute
-
Recipient Cells Are the Source of Hematologic Malignancies After Graft Failure and Mixed Chimerism in Adults With SCD Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-06 Mohamed A. E. Ali, Emily M. Limerick, Matthew M. Hsieh, Kalpana Upadhyaya, Xin Xu, Oswald Phang, Jean Pierre Kambala Mukendi, Katherine R. Calvo, Maria Lopez‐Ocasio, Pradeep Dagur, Courtney D. Fitzhugh
Hematopoietic cell transplant (HCT) is the only curative option for individuals with sickle cell disease (SCD). Traditionally, young patients with a human leukocyte antigen (HLA)-matched donor received myeloablative conditioning followed by HCT to completely replace recipient hematopoietic cells with healthy donor cells (full donor chimerism). Unfortunately, less than 15% of patients have an HLA-matched
-
Context and timing matters in acute myeloid leukemia: females are the superior hosts. Haematologica (IF 8.2) Pub Date : 2025-02-06 Kerstin B Kaufmann,Stephanie Z Xie
Not available.
-
Response to Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism. Haematologica (IF 8.2) Pub Date : 2025-02-06 Bengt Zöller,Jean M Connors
Not available.
-
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02). Haematologica (IF 8.2) Pub Date : 2025-02-06 Sarah Bertoli,Emilie Bérard,Pierre Peterlin,Romain Guieze,Yohan Desbrosses,Yosr Hicheri,Omar Benbrahim,Martin Carre,Corentin Orvain,Anne Banos,Marc Bernard,Emmanuel Gyan,Alain Saad,Safia Chebrek,Gabrielle Roth Guepin,Veronique Dorvaux,Laurence Sanhes,Maria Pilar Gallego-Hernanz,Carole Exbrayat,Laure Vincent,Chantal Himberlin,Célestine Simand,Norbert Vey,Cindy Fenoll,Ariane Mineur,Anne Huynh,Francois
Not available.
-
Comprehensive characterization of platelet function in dogs with hyperadrenocorticism. Haematologica (IF 8.2) Pub Date : 2025-02-06 Sanggu Kim,Dohee Lee,Preeti Kumari Chaudhary,Hakhyun Kim,Byeong-Teck Kang,Soochong Kim
Hyperadrenocorticism (HAC) leads to a hypercoagulable state and contributes to the risk of thromboembolic disease. Hypercoagulation in HAC occurs in both humans and dogs. Platelets play a major role in thrombosis and hemostasis, but no study has investigated platelet function in dogs with HAC. Thus, we aimed to characterize the platelet function and its molecular mechanism in dogs with HAC by using
-
The improved prognosis of FLT3-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world study using large-scale electronic health record data. Haematologica (IF 8.2) Pub Date : 2025-02-06 Matthew Schwede,Gladys Rodriguez,Vanessa E Kennedy,Solomon Henry,Douglas Wood,Gabriel N Mannis,Ravindra Majeti,Jonathan H Chen,Eran Bendavid,Tian Yi Zhang
Not available.
-
Update on long-term outcomes of a cohort of patients with TCF3::HLF positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation. Haematologica (IF 8.2) Pub Date : 2025-02-06 Aida Zeckanovic,Brice Mouttet,Luciana Vinti,Philip Ancliff,Benoît Brethon,Gunnar Cario,Sarah Elitzur,Volkan Hazar,Joachim Kunz,Anja Möricke,Jerry Stein,Yöntem Yaman,Jochen Buechner,Magnus Aasved Hjort,David O'Connor,Angus Hodder,Jack Bartram,Julia Alten,Draga Barbaric,Gabriele Escherich,Nicolas Boissel,Loïc Vasseur,Emmanuelle Clappier,Laure Farnault,Sarah Bonnet,Katharine Patrick,Martin Schrappe,Sema
Not available.
-
Deep immunophenotypic dissection and clinical impact of T cells in the follicular lymphoma microenvironment. Haematologica (IF 8.2) Pub Date : 2025-02-06 Sary El Daker,David Qualls,Andriy Derkach,Samida Beqaj,Leonardo Boiocchi,Venkatraman Seshan,Jeeyeon Baik,Menglei Zhu,Gilles Salles,Ahmet Dogan,Mikhail Roshal,Pallavi Galera
Follicular lymphoma (FL) is an indolent B cell lymphoma with a heterogenous disease course, and patients may not require immediate treatment upon diagnosis. Scrutiny of its microenvironment may provide key insights into lymphomagenesis and enhancement of therapeutic options. We analyzed the T-cell composition of a large, well-annotated follicular hyperplasia (FH; n=43) cohort utilizing standardized
-
Comment on: Multimorbidity, comorbidity, frailty, and venous thromboembolism. Haematologica (IF 8.2) Pub Date : 2025-02-06 Maria I Zervou,George N Goulielmos
Not available.
-
New bispecific antibodies in diffuse large B-cell lymphoma. Haematologica (IF 8.2) Pub Date : 2025-02-06 Adrian G Minson,Michael J Dickinson
The CD20xCD3 T-cell-engaging bispecific antibodies are a highly active new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Epcoritamab and glofitamab have both been approved in over thirty countries as monotherapy for DLBCL after two prior treatment lines; odronextamab has recent European approval, and mosunetuzumab is active and is being developed as
-
Multinational cohort study of intracranial hemorrhage in patients with brain metastases receiving anticoagulation. Haematologica (IF 8.2) Pub Date : 2025-02-06 Eva N Hamulyák,Tzu-Fei Wang,Lisa Baumann Kreuziger,Varun Iyengar,Brian J Carney,Ann Hoeben,Berna C Özdemir,Rosana D Cordova Serrano,Kristen M Sanfilippo,Shira Rozenblatt,Ludo F M Beenen,Shlomit Yust-Katz,Erez Halperin,Ariela Arad,Aharon Lubetsky,Marc Carrier,Benjamin Massat,Harry R Büller,Galia Spectre,Jeffrey I Zwicker,Avi Leader,
Not available.
-
Nontuberculous mycobacterial infections following teclistamab in multiple myeloma. Haematologica (IF 8.2) Pub Date : 2025-02-06 Matthew Ho,Luca Paruzzo,Janna Minehart,Teja Voruganti,Pooja Devi,Dan T Vogl,Adam D Cohen,Alfred L Garfall,Adam J Waxman,Shivani Kapur,Edward A Stadtmauer,Sandra Susanibar Adaniya,Sarah Longworth
Not available.
-
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma Leukemia (IF 12.8) Pub Date : 2025-02-05 Gayathri Ravi, Shambavi Richard, Shaji Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin Derman, P. Leif Bergsagel, Sham Mailankody, Philip McCarthy, Alok Shrestha, Lisa M. Kelly, Thomas Ly, Sharmila Das, Jerill Thorpe, Alison Maier, Divya Varun, Garnet Navarro, Michael R. Burgess, Kristen Hege, Ashley K. Koegel, Luciano J. Costa
-
STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4/STAT6/RRAGD/mTOR signaling in follicular lymphoma Leukemia (IF 12.8) Pub Date : 2025-02-05 Qiangqiang Shao, Karan Bedi, Isabella A. Malek, Kerby Shedden, Sami N. Malek
-
Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer J. Hematol. Oncol. (IF 29.5) Pub Date : 2025-02-05 Seungyeul Yoo, Ayushi S. Patel, Sarah Karam, Yi Zhong, Li Wang, Feng Jiang, Ranran Kong, Sharon Bikvan, Wenhui Wang, Abhilasha Sinha, Charles A. Powell, Jun Zhu, Hideo Watanabe
Small cell lung cancer (SCLC) is an aggressive and heterogeneous subtype, representing 15% of lung cancer cases. Although SCLC initially responds to etoposide and platinum (EP) chemotherapy, nearly all patients relapse with resistant tumors. While recent advances in immunotherapy have shown promise, only 10–20% of patients benefit, and effective stratification methods are lacking. The mechanisms of
-
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab Blood Cancer J. (IF 12.9) Pub Date : 2025-02-05 Yurou Chu, Biqi Zhou, Rui Gao, Miao Miao, Huiying Qiu, Xiaowen Tang, Ying Wang, Suning Chen, Liqing Kang, Depei Wu, Yang Xu
-
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases Blood Cancer J. (IF 12.9) Pub Date : 2025-02-05 Xiangke Xin, Wenli Zhang, Zhen Li, Ruirui Gui, Juan Wang, Liyun Ji, Yanli Zhang, Baijun Fang, Yongping Song, Yingling Zu, Jian Zhou
-
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention Blood Cancer J. (IF 12.9) Pub Date : 2025-02-05 Rodrigo Fonseca, Yuan Xiao Zhu, Laura A. Bruins, Joseph Ahmann, Cecilia de Bonolo Campos, Esteban Braggio, Xianfeng Chen, Mariano Arribas, Susie Darvish, Seth Welsh, Erin Meermeier, Kiran K. Mangalaparthi, Richard K. Kandasamy, Greg Ahmann, J. Erin Wiedmeier-Nutor, Akhilesh Pandey, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca
-
PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells. Blood (IF 21.0) Pub Date : 2025-02-05 Lingli He,Ting Zhao,Wei Zhong Leong,Azeem Sharda,Christina Mayerhofer,Shenglin Mei,Gracia M Bonilla,Juan Bautista Menendez-Gonzalez,Karin Gustafsson,Tsuyoshi Fukushima,Trine A Kristiansen,Ji-Won Lee,Yanxin Xu,Lei Chen,Jun Xia,Luis Angel Orozco,Bogdan Budnik,Ruslan Sadreyev,Zhixun Dou,David B Sykes,David T Scadden
Differentiation arrest and dependence on oxidative metabolism are features shared among genetically diverse acute myeloid leukemias (AML). A phenotypic CRISPR-Cas9 screen in AML identified dependence on phosphoseryl-tRNA kinase (PSTK), an atypical kinase required for the biosynthesis of all selenoproteins. In vivo, PSTK inhibition (PSTKi) impaired AML cell growth and leukemic stem cell self-renewal
-
EMZL at various sites: learning from each other. Blood (IF 21.0) Pub Date : 2025-02-05 Ming-Qing Du
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (EMZL) invariably develops from a background of chronic inflammatory disorder caused by a diverse chronic microbial infection and/or autoimmunity depending on the site. These chronic inflammatory/autoimmunity disorders trigger innate and acquired immune responses, generating a unique microenvironment at each site which drives clonal
-
Correction to “Secondary‐Type Mutations Do Not Impact Prognosis in Acute Myelogenous Leukemia AML With Mutated NPM1” Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-05
Wright MF, Pozdnyakova O, Hasserjian RP, et al., 2022. “Secondary-Type Mutations Do Not Impact Prognosis in Acute Myelogenous Leukemia AML With Mutated NPM1.” American Journal of Hematology 97, no. 12: E462–E465. https://doi.org/10.1002/ajh.26730. The title should read: Secondary-type mutations do not impact prognosis in AML with mutated NPM1. The words “acute myelogenous leukemia” should not appear
-
Differential Clinical and Immunological Impacts of Anti–T‐Lymphocyte Globulin (ATLG) vs. Anti‐Thymocyte Globulin (ATG) in Preventing Graft‐Versus‐Host Disease Post‐Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-05 Anne Beatrice Notarantonio, Stéphane Morisset, Romain Piucco, Michaël Pérès, Laura Boulangé, Alizée Alitcher, Jordan Brouard, Lucile Monchablon, Arnaud Campidelli, Siham El Ouahabi, Charles Guisnel, Charline Moulin, Céline Kicki, Gabrielle Roth‐Guepin, Pierre Feugier, Marcelo De Carvalho Bittencourt, Alice Aarnink, Maud D'Aveni‐Piney, Sébastien Hergalant, Simona Pagliuca, Marie Thérèse Rubio
Both anti‐T‐lymphocyte globulin (ATLG‐Grafalon) and anti‐thymocyte globulin (ATG‐Thymoglobulin) prevent acute and chronic graft‐versus‐host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Despite distinct manufacturing and biological characteristics, the two brands of rabbit anti‐lymphocyte globulins have never been compared in a prospective way. In this monocentric
-
2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-04 Debbie Jiang, Michael Wang, Allison P. Wheeler, Stacy E. Croteau
Clinical trial programs for inherited bleeding disorders feature an array of innovative prophylaxis options: engineered clotting factor concentrates, FVIIIa mimetics, gene therapies, and biologics to bolster thrombin generation (rebalancing agents). Increasingly, non‐hemophilia bleeding disorders and a broader demographic (females, children, and infants) are being incorporated into study populations
-
Sharpening the Tools to Get the Edge on Leukemia Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-04 Shai Shimony, Jacqueline S. Garcia
Conflicts of Interest J. Garcia has received research grants from AbbVie, Newave, Pfizer, and Genentech, and was an advisory board member or on the steering committee for AbbVie, Genentech, and Servier. S. shimony has no conflicts to declare.
-
Biology and Management of Acute Myeloid Leukemia With Mutated NPM1 Am. J. Hematol. (IF 10.1) Pub Date : 2025-02-04 Evan C. Chen, Shai Shimony, Marlise R. Luskin, Richard M. Stone
Mutations in nucleophosmin 1 (NPM1) are diseased‐defining genetic alterations encountered in approximately one‐third of cases of acute myeloid leukemia (AML). A mutation in NPM1 confers a more favorable prognosis; however, clinical outcomes of NPM1–mutated AML (NPM1mut AML) are diverse due to the heterogeneity of disease biology, patient characteristics, and treatment received. Research over the last
-
Correction: Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation J. Hematol. Oncol. (IF 29.5) Pub Date : 2025-02-03 Jing Dong, Shahram Arsang-Jang, Tao Zhang, Zhongyuan Chen, Yung-Tsi Bolon, Stephen Spellman, Raul Urrutia, Paul Auer, Wael Saber
Correction: Journal of Hematology & Oncology (2024) 17:104 https://doi.org/10.1186/s13045-024-01622-w The authors wish to note the following amendments to the affiliations and the funding in the original article. The affiliations should instead be as follows: • Wael Saber: CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI • Paul Auer:
-
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax Blood Cancer J. (IF 12.9) Pub Date : 2025-02-02 Caroline A. Coughlin, Dhanvantri Chahar, Marianna Lekakis, Abdessamad A. Youssfi, Lingxiao Li, Evan Roberts, Natalia Campos Gallego, Claude-Henry Volmar, Ola Landgren, Shaun Brothers, Anthony J. Griswold, Catalina Amador, Daniel Bilbao, Francesco Maura, Jonathan H. Schatz
-
Reactive oxygen species regulate early development of the intestinal macrophage-microbiome interface. Blood (IF 21.0) Pub Date : 2025-02-03 Zohreh Mansoori Moghadam,Bei Zhao,Candice Raynaud,Valentina Strohmeier,Jana Neuber,Anne Kathrin Lösslein,Sabrina Qureshi,Vitka Gres,Tara Ziegelbauer,Sebastian Baasch,Christoph Schell,Klaus Warnatz,Naohiro Inohara,Gabriel Nunez,Thomas Clavel,Stephan Patrick Rosshart,Julia Kolter,Philipp Henneke
Controlled development of cellular intestinal immunity in the face of dynamic microbiota emergence constitutes a major challenge in very early life, and a bottleneck for sustained growth and well-being. Early-onset inflammatory bowel disease (IBD) represents an extreme disturbance of intestinal immunity. It is a hallmark, and often the first manifestation of chronic granulomatous disease (CGD), caused
-
Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD. Blood (IF 21.0) Pub Date : 2025-02-03 Michael C Zaiken,Sujeong Jin,Cameron McDonald-Hyman,Christina Hartigan,Peter Sage,Keli L Hippen,Brent H Koehn,Angela Panoskaltsis-Mortari,Megan J Riddle,Cindy Eide,Jakub Tolar,Geoffrey R Hill,Leo Luznik,Corey S Cutler,Jerome Ritz,Leslie S Kean,Ageliki Tsagaratou,Anjana Rao,Bruce R Blazar
Chronic graft-versus-host disease (cGVHD) is the leading cause of morbidity and non-relapse associated mortality following allogeneic hematopoietic cell transplantation (aHSCT). Treating steroid resistant/refractory cGVHD remains challenging. Epigenetic regulators can have global transcriptional effects that control donor T-cell responses. We previously showed that inhibiting histone lysine motifs
-
How I approach pharmacological thromboprophylaxis in children. Blood (IF 21.0) Pub Date : 2025-02-03 Anthony A Sochet,Amy Kiskaddon,Neil A Goldenberg
The incidence of venous thromboembolism in children continues to rise, with the most recent analysis from the Pediatric Hospital Information Systems database in the United States reporting a 200-fold increase in pediatric hospitalization-related venous thromboembolism diagnoses over the past two decades. In the past decade, several pediatric venous thromboembolism risk prediction models have been published
-
IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy. Blood (IF 21.0) Pub Date : 2025-02-03 Marcos Garcia-Lacarte,Sara C Grijalba,Javier Melchor Sánchez,Marien Pascual,Enrique Goni,Inigo Clemente-Larramendi,Sandra Morales-Sanchez,Maria A Burrell,Oscar Blanco,Adrian Arnaiz-Leché,Blanca S Berrozpe,Maria Amann,Christian Klein,Pablo Umaña,Miguel Angel Canales,Jose Angel Martinez-Climent,Juan Jose Lasarte,Pablo Sarobe,Francisco J Novo,Sergio Roa
The contribution of IL-10 secreted by tumoral B cells to the progression and shaping of the microenvironment in diffuse large B-cell lymphoma (DLBCL) with activated B-cell (ABC) phenotype is not yet completely understood. To shed light on this issue, we generated an immunocompetent mouse model of ABC-DLBCL with conditional knock-out of IL-10 specifically in malignant B cells. Paradoxically, these mice
-
Patterns and variations of copy number alterations in acute myeloid leukemia: insights from the LeukAtlas database Leukemia (IF 12.8) Pub Date : 2025-02-02 Yanxun Su, Zhenxian Han, Yutong Ji, Anqi Liu, Dong Zou, Lina Yan, Dan Liu, Zhang Zhang, Qian-Fei Wang
-
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier Blood Cancer J. (IF 12.9) Pub Date : 2025-02-01 M. L. Morales, H. Cano, B. de la Morena-Barrio, J. L. Vives-Corrons, E. J. Cuenca-Zamora, P. Garrido-Rodríguez, C. Bento, J. Pereira, J. Martínez Nieto, T. H. Chen-Liang, J. L. Fuster, S. Caracena, M. L. Lozano, R. Teruel-Montoya, J. Corral, F. Ferrer-Marín
-
Pioneering a new field of computational pharmacophenomics to unlock the life-saving potential of existing medicines. Lancet Haematol. (IF 15.4) Pub Date : 2025-02-01 David C Fajgenbaum,Sally Nijim,Grant Mitchell,Matej Macak,Chris Bizon,Alexander Tropsha,David Koslicki
-
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study. Lancet Haematol. (IF 15.4) Pub Date : 2025-02-01 Pasquale Niscola
-
Optimising quadruplet regimens to broaden eligibility in multiple myeloma. Lancet Haematol. (IF 15.4) Pub Date : 2025-02-01 Tanya M Wildes
-
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study. Lancet Haematol. (IF 15.4) Pub Date : 2025-02-01 Hege Kristin Gravdahl Garelius,Timothy Bagguley,Adele Taylor,Pierre Fenaux,David Bowen,Argiris Symeonidis,Moshe Mittelmann,Reinhard Stauder,Jaroslav Čermák,Guillermo Sanz,Saskia Langemeijer,Luca Malcovati,Ulrich Germing,Laurence Sanhes,Maud d'Aveni,Dominic Culligan,Ioannis Kotsianidis,Karin A Koinig,Corine van Marrewijk,Simon Crouch,Theo deWitte,Alexandra Smith,Eva Hellström-Lindberg
BACKGROUND In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk myelodysplastic syndromes from the European MDS (EUMDS) Registry, we showed that patients treated with ESAs had longer survival compared with patients who receive red blood cell transfusion (RBCT). In this study, with a longer follow up time and more patients included, we aimed to assess long-term effects
-
Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet. Lancet Haematol. (IF 15.4) Pub Date : 2025-02-01 Vincent Ribrag,Dominique Bron,Grzegorz Rymkiewicz,Dieter Hoelzer,Judit Jørgensen,Aythami de Armas-Castellano,Maria Trujillo-Martín,Pierre Fenaux,Luca Malcovati,Natacha Bolaños,Josep-Maria Ribera,Charles Herbaux,Clémentine Sarkozy,Pier Luigi Zinzani,Jan Walewski,Martine E D Chamuleau
Burkitt lymphoma is a rare lymphoma entity that represents less than 5% of adult lymphomas. Although prognosis has improved with dose-dense therapy, Burkitt lymphoma remains an area of clinical and biological research with specificities due to the high incidence of CNS involvement and tumour lysis syndrome in patients with a high tumour burden. Few consensus recommendations are available concerning
-
Inclusion matters: progress in haematological trials for pregnant individuals. Lancet Haematol. (IF 15.4) Pub Date : 2025-02-01 The Lancet Haematology
-
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial. Lancet Haematol. (IF 15.4) Pub Date : 2025-02-01 Frida Bugge Askeland,Einar Haukås,Tobias S Slørdahl,Anja Klostergaard,Tatjana Alexandersen,Anna Lysén,Pegah Abdollahi,Lene Kongsgaard Nielsen,Emil Hermansen,Fredrik Schjesvold
BACKGROUND Adding anti-CD38 monoclonal antibodies to standard therapies can improve outcomes in patients with multiple myeloma. Long-term treatment with corticosteroids increases the risk of infection. We aimed to evaluate the safety and activity of isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone in patients with newly diagnosed multiple myeloma ineligible for autologous haematopoietic
-
The origins of the definition of complete remission in acute myeloid leukemia. Haematologica (IF 8.2) Pub Date : 2025-02-01 Mark R Litzow
-
Alessandro Pileri: an enthusiastic pioneer of modern hematology. Haematologica (IF 8.2) Pub Date : 2025-02-01 Mario Boccadoro,Paolo Corradini,Massimo Massaia,Corrado Tarella
-
Introduction to the Review Series on Myelodysplasia. Haematologica (IF 8.2) Pub Date : 2025-02-01 Moshe Mittelman
-
Adopting the new iStopMM-based criteria for light-chain monoclonal gammopathy of undetermined significance: an ongoing debate. Haematologica (IF 8.2) Pub Date : 2025-02-01 Dor Shpitzer,Yael C Cohen,Tamir Shragai,Guy Melamed,Anat Reiner-Benaim,Irit Avivi
-
Multiple phenotypes and epigenetic profiles in a three-generation family history with GATA2 deficiency Leukemia (IF 12.8) Pub Date : 2025-01-31 Damia Romero-Moya, Joan Pera, Oskar Marin-Bejar, Eric Torralba-Sales, Laura Murillo-Sanjuán, Cristina Diaz-de-Heredia, Julia Montoro, Javier Rodríguez-Ubreva, Alessandro Liquori, José Cervera, Marcin W. Wlodarski, Albert Català, Alessandra Giorgetti
-
GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome Blood Cancer J. (IF 12.9) Pub Date : 2025-01-30 Laetitia Largeaud, Vincent Fregona, Laura A. Jamrog, Camille Hamelle, Stéphanie Dufrechou, Naïs Prade, Esmaa Sellam, Pauline Enfedaque, Manon Bayet, Sylvie Hébrard, Mathieu Bouttier, Christine Didier, Bastien Gerby, Eric Delabesse, Marlène Pasquet, Cyril Broccardo
-
Balancing the Scales: Optimizing Reporting of Infection Rates in Clinical Trials of Bispecific Antibodies in Multiple Myeloma Am. J. Hematol. (IF 10.1) Pub Date : 2025-01-31 Joshua Richter, Madhav V. Dhodapkar, Mengying Li, Mina Awad, Christian Hampp, Kate Knorr, Glenn Kroog, Tito Roccia, Naresh Bumma
Conflicts of Interest J.R. reports consulting or participation in an advisory role for Takeda, Adaptive Biotechnologies, Karyopharm Therapeutics, Antengene, Sanofi, Genentech, Pfizer, Janssen, AbbVie, Bristol Myers Squibb/Celgene, and Regeneron; speakers' bureau engagement for Celgene, Janssen, Bristol Myers Squibb, Sanofi, and Adaptive biotechnologies; and reimbursement for travel, accommodation,
-
Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma Leukemia (IF 12.8) Pub Date : 2025-01-30 Zhannan Han, Zhibo Yan, Zhehan Ma, Yihui Wang, Maja Beus, Junqi Lu, Loren B. Weidenhammer, Kiran Lakhani, Jingyun Lee, John D. Civils, Cristina M. Furdui, Liang Liu, Jian Wu, Yubin Kang, Erhard Bieberich, Lawrence H. Boise, Mikhail A. Nikiforov
-
MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial. Blood (IF 21.0) Pub Date : 2025-01-30 Moritz Fürstenau,Sandra Robrecht,Christof Schneider,Eugen Tausch,Adam Giza,Matthias Ritgen,Jörg T Bittenbring,Holger Hebart,Björn Schöttker,Anna Lena Lena Illert,Ullrich Graeven,Andrea Stoltefuss,Bernhard Heinrich,Robert Eckert,Anna-Maria Fink,Janina Stumpf,Kirsten Fischer,Othman Al-Sawaf,Florian Simon,Fanni Kleinert,Jonathan Weiss,Karl-Anton Kreuzer,Anke Schilhabel,Monika Brüggemann,Petra Langerbeins
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were enrolled and two patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of one prior therapy